We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study.
- Authors
Terence Ng; Ying Yun Lee; Jung-woo Chae; Angie Hui Ling Yeo; Maung Shwe; Yan Xiang Gan; Ng, Raymond C. H.; Pat Pak Yan Chu; Chiea Chuen Khor; Han Kiat Ho; Alexandre Chan; Ng, Terence; Lee, Ying Yun; Chae, Jung-Woo; Yeo, Angie Hui Ling; Shwe, Maung; Gan, Yan Xiang; Chu, Pat Pak Yan; Khor, Chiea Chuen; Ho, Han Kiat
- Abstract
<bold>Background: </bold>Preliminary evidence suggests that changes in plasma brain-derived neurotrophic factor (BDNF) levels may contribute to the occurrence of chemotherapy-associated cognitive impairment (CACI), and a previous study suggested that carriers of the BDNF Met homozygous genotype are protected from CACI.<bold>Methods: </bold>This multicenter, prospective cohort study involved chemotherapy-receiving early-stage breast cancer (ESBC) patients. Self-perceived cognitive function was longitudinally assessed using the validated FACT-Cog (ver. 3) across three time points: Prior to chemotherapy (T1), during chemotherapy (T2), and at the end of chemotherapy (T3). Plasma BDNF levels were quantified using enzyme-linked immunosorbent assay. Genotyping was performed using Sanger Sequencing.<bold>Results: </bold>A total of 51 chemotherapy-receiving ESBC patients (mean age: 52.6 ± 9.5 years) were recruited, and 11 patients (21.6%) reported subjective cognitive impairment post-chemotherapy. Overall, there was a reduction in median plasma BDNF levels over time (T1: 5423.0 pg/ml; T2: 5313.6 pg/ml; T3: 4050.3 pg/ml; p < 0.01). After adjusting for confounding factors, longitudinal analysis revealed that BDNF levels were associated with self-reported concentration deficit (p = 0.032). Carriers of Val/Val (p = 0.011) and Val/Met (p = 0.003) BDNF genotypes demonstrated a significant reduction in plasma BDNF levels over time; however, plasma BDNF levels were similar across all time points among Met homozygous carriers (p = 0.107).<bold>Conclusion: </bold>There was a statistically significant change in BDNF levels post-chemotherapy in ESBC patients, and plasma BDNF levels were associated with self-perceived concentration deficit in patients receiving chemotherapy.
- Subjects
NEUROTROPHINS; MILD cognitive impairment; CANCER chemotherapy; BREAST cancer; NERVE growth factor; BREAST tumors; DISEASE susceptibility; GENETIC polymorphisms; GENETIC techniques; NERVE tissue proteins; TUMOR classification; GENOTYPES
- Publication
BMC Cancer, 2017, Vol 17, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-017-3861-9